Table 1.
General baseline data, overall and by period, of the HIV cohort from OutcomeRea™
| Global (n = 630) |
1997–2006 (n = 215) |
2007–2015 (n = 336) |
2016–2020 (n = 79) |
p value | |
|---|---|---|---|---|---|
| Age (year) | 46.7 [38; 55] | 41.8 [36; 51] | 48.1 [39; 55] | 54.3 [44; 58] | < 0.001 |
| Body mass index | 21.8 [19; 25] | 20.8 [19; 23] | 22.7 [20; 25] | 23 [20; 27] | < 0.001 |
| Katz independence scale | 6 [6; 6] | NA | 6 [6; 6] | 6 [6; 6] | 0.991 |
| Sex (male) | 440 (69.8%) | 143 (66.5%) | 242 (72%) | 55 (69.6%) | 0.350 |
| Diabetes | 48 (7.6%) | 3 (1.4%) | 35 (10.4%) | 10 (12.7%) | < 0.001 |
| Obesity | 34 (5.9%) | 4 (2.5%) | 18 (5.4%) | 12 (15.2%) | < 0.001 |
| Substance abuse | 79 (13.7%) | 30 (18.6%) | 40 (12%) | 9 (11.4%) | 0.464 |
| Precariousness (n = 55, 206, 59) | 221 (69.1%) | 40 (72.7%) | 142 (68.9%) | 40 (66.1%) | 0.446 |
| Hepatitis | |||||
| B | 25 (4%) | 6 (2.8%) | 18 (5.4%) | 1 (1.3%) | 0.901 |
| C | 66 (10.5%) | 13 (6%) | 46 (13.7%) | 7 (8.9%) | 0.098 |
| Chronic disease (KNAUS) | |||||
| Hepatic | 47 (7.5%) | 11 (5.1%) | 30 (8.9%) | 6 (7.6%) | 0.229 |
| Cardiovascular | 45 (7.1%) | 8 (3.7%) | 31 (9.2%) | 6 (7.6%) | 0.066 |
| Renal | 41 (6.5%) | 7 (3.3%) | 27 (8%) | 7 (8.9%) | 0.027 |
| Respiratory | 43 (6.8%) | 4 (1.9%) | 31 (9.2%) | 8 (10.1%) | 0.001 |
| Solid neoplasia | 23 (3.6%) | 1 (0.5%) | 15 (4.5%) | 7 (8.9%) | < 0.001 |
| Non-AIDS hemopathy | 8 (1.5%) | 1 (0.7%) | 5 (1.6%) | 2 (2.7%) | 0.134 |
| Pre-admission immunosuppression (excluding HIV/AIDS) | |||||
| Aplasia | 28 (4.4%) | 11 (5.1%) | 14 (4.2%) | 3 (3.8%) | 0.560 |
| Corticoid | 21 (3.3%) | 5 (2.3%) | 12 (3.6%) | 4 (5.1%) | 0.226 |
| Anticancer chemotherapy | 91 (14.4%) | 26 (12.1%) | 56 (16.7%) | 9 (11.4%) | 0.644 |
| SOT | 6 (0.9%) | 0 | 4 (1.2%) | 2 (2.5%) | 0.037 |
| Other | 16 (2.5%) | 0 | 10 (3%) | 6 (7.6%) | < 0.001 |
| Pre-ICU hospitalization stay (day) | 1 [1; 3] | 1 [1; 5] | 1 [1; 3] | 1 [1; 2] | 0.324 |
| Medical reason for ICU admission | 591 (94%) | 199 (92.6%) | 318 (94.6%) | 74 (94.9%) | 0.309 |
| SOFA upon ICU admission | 5 [2; 8] | 5 [3; 8] | 5 [2; 8] | 6 [1; 9] | 0.668 |
| Main purpose for ICU admission* | 0.626 | ||||
| Multivisceral failure | 12 (1.9%) | 6 (2.8%) | 3 (0.9%) | 3 (3.8%) | |
| Septic shock | 77 (12.3%) | 19 (8.9%) | 48 (14.4%) | 10 (12.8%) | |
| Hemorrhagic shock | 14 (2.2%) | 6 (2.8%) | 6 (1.8%) | 2 (2.6%) | |
| Cardiogenic shock | 8 (1.3%) | 4 (1.9%) | 2 (0.6%) | 2 (2.6%) | |
| Shock (other) | 18 (2.9%) | 6 (2.8%) | 10 (3%) | 2 (2.6%) | |
| Acute respiratory distress | 223 (35.6%) | 85 (39.7%) | 106 (31.7%) | 32 (41%) | |
| COPD decompensation | 4 (0.6%) | 0 | 4 (1.2%) | 0 | |
| Acute renal failure | 53 (8.5%) | 14 (6.5%) | 34 (10.2%) | 5 (6.4%) | |
| Coma | 109 (17.4%) | 40 (18.7%) | 57 (17.1%) | 12 (15.4%) | |
| Continuous monitoring | 103 (16.4%) | 33 (15.4%) | 60 (18%) | 10 (12.8%) | |
| Scheduled surgery | 5 (0.8%) | 1 (0.5%) | 4 (1.2%) | 0 | |
| Syndromic diagnosis on admission* | |||||
| Infection | 342 (54.3%) | 131 (60.9%) | 166 (49.5%) | 45 (57%) | 0.133 |
| Bacteremia | 29 (4.6%) | 15 (7%) | 9 (2.7%) | 5 (6.3%) | |
| Pneumonia | 179 (28.4%) | 80 (37.2%) | 74 (22%) | 25 (31.6%) | |
| Meningitis | 52 (8.2%) | 27 (12.6%) | 16 (4.8%) | 9 (11.4%) | |
| Cardiovascular | 40 (6.3%) | 14 (6.5%) | 22 (6.5%) | 4 (5.1%) | 0.882 |
| Cardiorespiratory arrest | 19 (3%) | 6 (2.8%) | 9 (2.7%) | 4 (5.1%) | |
| Acute lung edema | 13 (2.1%) | 4 (1.9%) | 9 (2.7%) | 0 | |
| Myocardial infarction | 3 (0.5%) | 3 (1.4%) | 0 | 0 | |
| Stroke | 5 (0.8%) | 1 (0.5%) | 4 (1.2%) | 0 | |
Bold indicates the significance of the result (p < 0.05)
AIDS acquired immunodeficiency syndrome, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, SOFA sepsis-related organ failure assessment, SOT solid organ transplant
*Only one proposition for each patient